Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Expression and Prognostic Value of ILK and YAP1 in Glioma

The Expression and Prognostic Value of ILK and YAP1 in Glioma Integrin-linked kinase (ILK) is a widely expressed serine/threonine-protein kinase that has been implicated in cancer development, progression, and metastasis. Yes-associated protein (YAP), as the most important effector of Hippo signaling pathway, which is considered to be a tumor suppressor pathway, acts as an oncogene in a variety of human cancers. The present study aimed to explore the expression of ILK and YAP1, the relationship between them, and the effect of ILK, YAP1 on prognosis in gliomas. Immunohistochemistry was used to examine the expression of ILK and YAP1. The χ2 test analyzes the relationship between ILK, YAP1, and pathologic parameters. The Spearman correlation analyzes the relationship between ILK and YAP1. Survival analysis was used to investigate the effect of ILK and YAP1 on prognosis. High expression of ILK was associated with the age above 50 (P=0.003), higher World Health Organization (WHO) grade (P<0.001), recurrence (P<0.001), and Ki-67 expression≥10% (P<0.001). High expression of YAP1 was associated with higher WHO grade (P<0.001), recurrence (P=0.043), and Ki-67 expression ≥10% (P=0.037). In lower grade gliomas, the high expression rate of ILK in isocitrate dehydrogenase 1 wild-type was higher than that in isocitrate dehydrogenase 1 mutant (P=0.048). The high expression rate of YAP1 in 1p19q non-codeletion was higher than that in 1p19q codeletion (P=0.022). There was a positive correlation between ILK and YAP1 (r=0.344). The patients with high expression of ILK and YAP1 had worse OS and PFS. As an upstream factor of the Hippo signaling pathway, ILK may affect the development and prognosis of gliomas by regulating YAP1. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

The Expression and Prognostic Value of ILK and YAP1 in Glioma

Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/the-expression-and-prognostic-value-of-ilk-and-yap1-in-glioma-01kQq01v8i
Publisher
Wolters Kluwer Health
Copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1062-3345
eISSN
1533-4058
DOI
10.1097/pai.0000000000000984
Publisher site
See Article on Publisher Site

Abstract

Integrin-linked kinase (ILK) is a widely expressed serine/threonine-protein kinase that has been implicated in cancer development, progression, and metastasis. Yes-associated protein (YAP), as the most important effector of Hippo signaling pathway, which is considered to be a tumor suppressor pathway, acts as an oncogene in a variety of human cancers. The present study aimed to explore the expression of ILK and YAP1, the relationship between them, and the effect of ILK, YAP1 on prognosis in gliomas. Immunohistochemistry was used to examine the expression of ILK and YAP1. The χ2 test analyzes the relationship between ILK, YAP1, and pathologic parameters. The Spearman correlation analyzes the relationship between ILK and YAP1. Survival analysis was used to investigate the effect of ILK and YAP1 on prognosis. High expression of ILK was associated with the age above 50 (P=0.003), higher World Health Organization (WHO) grade (P<0.001), recurrence (P<0.001), and Ki-67 expression≥10% (P<0.001). High expression of YAP1 was associated with higher WHO grade (P<0.001), recurrence (P=0.043), and Ki-67 expression ≥10% (P=0.037). In lower grade gliomas, the high expression rate of ILK in isocitrate dehydrogenase 1 wild-type was higher than that in isocitrate dehydrogenase 1 mutant (P=0.048). The high expression rate of YAP1 in 1p19q non-codeletion was higher than that in 1p19q codeletion (P=0.022). There was a positive correlation between ILK and YAP1 (r=0.344). The patients with high expression of ILK and YAP1 had worse OS and PFS. As an upstream factor of the Hippo signaling pathway, ILK may affect the development and prognosis of gliomas by regulating YAP1.

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Mar 9, 2022

References

  • Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma
  • Glioma
  • Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas
  • Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors
  • Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC Trial
  • Molecular targets of glioma invasion
  • Recent advances of the Hippo/YAP signaling pathway in brain development and glioma
  • The Hippo pathway as a drug target in gastric cancer
  • Expression of hippo pathway in colorectal cancer
  • Effects of the hippo signaling pathway in human gastric cancer
  • Yes-associated protein 65 (YAP) expands neural progenitors and regulates Pax3 expression in the neural plate border zone
  • Yes-associated protein 1 is widely expressed in human brain tumors and promotes glioblastoma growth
  • Expression of Yes-associated protein 1 gene and protein in oral squamous cell carcinoma
  • Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase
  • Role of the integrin-linked kinase (ILK)/Rictor complex in TGFβ-1-induced epithelial-mesenchymal transition (EMT)
  • Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression
  • Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells
  • The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)
  • Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1)
  • Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity
  • RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance
  • Overexpression of ILK promotes temozolomide resistance in glioma cells
  • Proteomics reveals protein phosphatase 1γ as a biomarker associated with Hippo signal pathway in glioma
  • Clinical significance of integrin-linked kinase in laryngeal squamous cell carcinoma
  • Small interfering RNA targeting ILK inhibits EMT in human peritoneal mesothelial cells through phosphorylation of GSK‑3β
  • Integrin-linked kinase—essential roles in physiology and cancer biology
  • The importance of integrin-linked kinase in the regulation of bladder cancer invasion
  • Overexpression of integrin-linked kinase (ILK) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer
  • Integrin-linked kinase is involved in the proliferation and invasion of esophageal squamous cell carcinoma
  • Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma
  • Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth
  • Integrin-linked kinase (ILK) regulation of the cell viability in PTEN mutant glioblastoma and in vitro inhibition by the specific COX-2 inhibitor NS-398
  • The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP
  • YAP/TAZ at the roots of cancer
  • YAP promotes migration and invasion of human glioma cells
  • Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence
  • Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells